Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silycus-21 in Cushing’s disease
2024-518869-99-00Phase 2Authorised
- Sponsor
- IBI Lorenzini
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of silibinin in Corticotropin adenoma (ACTHoma), sponsored by IBI Lorenzini. Primary endpoints: Efficacy on biochemical markers of Cushing’s disease at 12 weeks and Composite biochemical response at 12 weeks. Planned start Nov 2024; status: authorised.
02
Drugs
silibinin
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2024-518869-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518869-99-00.